COSCIENS Biopharma Files June 2025 6-K Report
Ticker: CSCIF · Form: 6-K · Filed: Jun 9, 2025 · CIK: 1113423
Sentiment: neutral
Topics: 6-K, foreign-private-issuer, corporate-filing
TL;DR
COSCS Biopharma (formerly Aeterna Zentaris) filed its June 6-K, confirming its status as a foreign private issuer.
AI Summary
COSCIENS Biopharma Inc. filed a Form 6-K on June 9, 2025, reporting for the month of June 2025. The company, formerly known as Aeterna Zentaris Inc. and AETERNA LABORATORIES INC, is a foreign private issuer. Its principal executive office is located in Toronto, Ontario, Canada.
Why It Matters
This filing indicates ongoing reporting requirements for COSCIENS Biopharma Inc. as a foreign private issuer, providing transparency to investors about its corporate activities.
Risk Assessment
Risk Level: low — This filing is a routine report and does not contain new material financial or operational information that would inherently increase risk.
Key Players & Entities
- COSCIENS Biopharma Inc. (company) — Filer
- Aeterna Zentaris Inc. (company) — Former company name
- AETERNA LABORATORIES INC (company) — Former company name
- Norton Rose Fulbright Canada, LLP (company) — Legal counsel/address provider
- 20250609 (date) — Filing date
FAQ
What is the purpose of this Form 6-K filing?
This Form 6-K is a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934, for the month of June 2025.
What is the filing date of this report?
The filing date, as indicated by the accession number and header, is June 9, 2025.
What are the former names of COSCIENS Biopharma Inc.?
The company was formerly known as Aeterna Zentaris Inc. and AETERNA LABORATORIES INC.
Where is the principal executive office of COSCIENS Biopharma Inc. located?
The principal executive office is located at c/o Norton Rose Fulbright Canada, LLP, 222 Bay Street, Suite 3000, PO Box 53, Toronto ON M5K 1E7.
Does COSCIENS Biopharma Inc. file annual reports under Form 20-F or Form 40-F?
The registrant indicates it files annual reports under Form 20-F.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on June 9, 2025 regarding COSCIENS Biopharma Inc. (CSCIF).